Roughly 8 million American adults live with psoriasis, and about one in three will also develop psoriatic arthritis. The plaques on the skin are the visible part — the underlying inflammation affects joints, blood vessels, and metabolism, which is why the disease is managed as a systemic condition, not just a skin condition.
Psoriasis begins when the immune system mistakenly identifies components of the skin as a threat. Dendritic cells in the skin activate T lymphocytes, which then migrate into the epidermis and release inflammatory cytokines. The dominant pathway is the IL-23 / IL-17 axis: dendritic cells produce IL-23, which drives T cells to produce IL-17 and IL-22, which in turn stimulate keratinocytes to proliferate abnormally fast.
The result is visible: a normal skin cell takes about 28 days to move from the basal layer to the surface and shed. In a psoriatic plaque, that cycle is compressed to 3 to 5 days. The epidermis thickens (acanthosis), the rete ridges elongate downward, and the stratum corneum loses its normal protective architecture — producing the characteristic silvery scale and salmon-colored base.
TNF-α amplifies the inflammatory loop and is one of the reasons psoriasis behaves as a systemic disease. Elevated TNF-α and IL-17 circulate throughout the body, contributing to the metabolic and cardiovascular risk that accompanies psoriasis even when skin involvement is limited. This is why treating the skin alone often does not fully address the disease.
Genetics play a substantial role. About 40 percent of patients have a family history, and specific HLA types (particularly HLA-Cw6) are strongly associated with early-onset psoriasis. However, genetics alone do not cause psoriasis — environmental triggers such as streptococcal infection, stress, medications (lithium, beta-blockers, antimalarials), and skin trauma (the Koebner phenomenon) typically precede the first flare.
Psoriatic arthritis develops in roughly 30 percent of patients and follows the same immune pathway. It can affect any joint but most commonly affects the distal interphalangeal joints of the fingers, the spine, and the entheses — the points where tendons and ligaments attach to bone. Early recognition matters: joint damage that accumulates before treatment can become permanent.
Skin-resident immune cell recognizes a trigger and produces IL-23.
IL-23 drives naïve T cells toward the Th17 phenotype.
Th17 cells release IL-17A and IL-22, driving keratinocyte proliferation.
Epidermis thickens, scale forms, and synovial inflammation develops in some patients.
Psoriasis is classified by the pattern and distribution of lesions. The subtype influences treatment intensity and prognosis, and different subtypes can coexist in the same patient.
The classic form. Well-demarcated, salmon-pink plaques with silvery-white scale, typically on elbows, knees, scalp, lower back, and buttocks. Symmetric distribution. Chronic and persistent. The target of most systemic therapy development.
Sudden eruption of small, drop-like lesions on the trunk and proximal limbs. Frequently follows a streptococcal throat infection by 2 to 3 weeks. Often resolves spontaneously but may evolve into chronic plaque psoriasis. Common in children and young adults.
Involves skin folds — axillae, groin, inframammary, intergluteal cleft. Presents as smooth, shiny, red plaques without the silvery scale seen elsewhere. Frequently misdiagnosed as fungal infection or intertrigo. More common in patients with obesity or diabetes.
Localized (palms and soles — palmoplantar pustulosis) or generalized. Presents as sterile pustules on erythematous skin. The generalized form is a medical emergency requiring hospitalization. Triggered by infection, medications (especially systemic steroids), pregnancy, or hypocalcemia.
Widespread involvement of > 90% body surface area. The skin loses its barrier function, leading to temperature dysregulation, fluid loss, and risk of infection and heart failure. A dermatologic emergency requiring hospitalization and intensive supportive care.
Psoriasis severity is measured by the extent of skin involvement (BSA or PASI) and by its impact on quality of life (DLQI). Treatment decisions are based on both.
Limited skin involvement. Typically managed with topical therapy — corticosteroids, vitamin D analogs, or calcineurin inhibitors. Response typically evaluated after 4 to 8 weeks.
More extensive but still limited. May respond to targeted phototherapy (NB-UVB) or to topicals plus a systemic agent for flares. Decision often guided by location — face, hands, and genitals count as severe regardless of area.
Typically warrants systemic therapy or phototherapy. Biologics, oral systemic agents, or NB-UVB. Most clinical trials of new drugs enroll patients in this range.
Extensive involvement. Biologic therapy is usually first-line. Higher risk of psoriatic arthritis, metabolic syndrome, and cardiovascular events. Aggressive treatment is generally warranted.
The classic approach was to escalate step by step. Modern practice favors starting with the treatment that matches disease severity — with biologics often appropriate first-line for moderate-to-severe disease.
Corticosteroids, vitamin D analogs (calcipotriene), and calcineurin inhibitors. Applied directly to plaques. Combining a steroid with a vitamin D analog is more effective than either alone and reduces steroid-related skin thinning.
Best for limited disease. Also used as an adjunct to systemic therapy for stubborn plaques. Do not use high-potency steroids on the face, groin, or skin folds.
Narrowband UVB (NB-UVB) is the most commonly used form — 2 to 3 sessions per week in a dermatology office or at home with a prescribed unit. Excimer laser targets individual plaques with higher-dose UVB. PUVA (psoralen + UVA) is more effective but carries higher long-term skin cancer risk and is used less often.
Response typically seen in 20 to 30 sessions. Phototherapy is a reasonable option for widespread disease when systemic therapy is not appropriate — but requires regular visits, which is often the limiting factor.
Methotrexate is the most widely used oral systemic — effective for both skin and joints, requires folic acid supplementation and periodic liver and blood monitoring. Apremilast is a PDE4 inhibitor with a favorable safety profile but modest efficacy — useful for patients who cannot take methotrexate or biologics.
Cyclosporine works quickly but is limited to short courses due to kidney toxicity and hypertension. Acitretin is a retinoid — effective but teratogenic and requires long-term contraception.
Monoclonal antibodies that target specific cytokines in the psoriasis pathway. Four classes are available: TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab), IL-17 inhibitors (secukinumab, ixekizumab, brodalumab), IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), and IL-12/23 inhibitor (ustekinumab).
IL-17 and IL-23 inhibitors achieve PASI 90 in 70 to 80 percent of patients and PASI 100 in 40 to 50 percent. Given by subcutaneous injection or IV infusion at intervals of 4 to 12 weeks. All require baseline tuberculosis screening and monitoring for infection.
Multiple biosimilars to adalimumab, etanercept, and infliximab have entered the U.S. market, substantially reducing cost for TNF-inhibitor therapy. Efficacy is comparable to the reference product. Biosimilars for IL-17 and IL-23 inhibitors are beginning to appear as patents expire.
Newer agents in development include oral IL-23 receptor antagonists and topical tapinarof. The trajectory is toward higher efficacy with more convenient administration — including oral options — over the next decade.
Chronic systemic inflammation in psoriasis affects organs beyond the skin. Regular screening is part of good psoriasis care.
Affects about 30% of patients. Screen at every visit for joint pain, morning stiffness, dactylitis ("sausage fingers"), and enthesitis (heel pain, elbow pain). Early treatment prevents irreversible joint damage. Rheumatology referral when suspected.
Psoriasis roughly doubles cardiovascular risk — independent of traditional factors. Screen for hypertension, dyslipidemia, diabetes, and obesity. Severe psoriasis is associated with myocardial infarction at rates comparable to diabetes. Lifestyle modification and cardiovascular risk management are part of treatment.
Depression and anxiety are substantially more common in psoriasis than in the general population. Roughly 1 in 4 patients experience depression. Suicidal ideation is elevated. Screening with PHQ-9 is reasonable; treatment often includes psychological support alongside dermatologic care.
Crohn's disease and ulcerative colitis are more common in psoriasis. The relationship matters for treatment choice — IL-17 inhibitors can worsen IBD, while IL-12/23 and IL-23 inhibitors are generally safe and may improve it. Screen for GI symptoms before starting biologic therapy.
Biologic therapies for psoriasis are among the most expensive chronic medications. Without insurance, annual costs can range from $60,000 to $120,000 depending on the drug. Traditional topicals (corticosteroids, calcipotriene) and oral agents (methotrexate, cyclosporine) are generic and inexpensive, but they are not always sufficient for moderate-to-severe disease.
The practical reality is that most commercially insured patients pay little to nothing for biologics through manufacturer copay assistance programs. Every major biologic for psoriasis has a patient support program that covers most or all of the out-of-pocket cost for commercially insured patients. The savings card is typically obtained from the manufacturer or through the prescribing dermatologist's office. Biosimilars have further reduced pricing for TNF-inhibitor therapy.
Patients on Medicare, Medicaid, or VA benefits cannot legally receive manufacturer copay assistance — but are eligible for grants from independent patient assistance foundations (HealthWell Foundation, PAN Foundation, Patient Advocate Foundation) that provide the same relief. Every specialty pharmacy that dispenses a biologic has staff whose entire job is to help navigate these programs, and the dermatologist's office usually has a dedicated coordinator as well.
For generics and topicals: the same generic cream or tablet can cost several times more at one licensed pharmacy than another. A live prescription price comparison shows the current range in about two minutes, and the same logic applies to every generic on a patient's list. For a first-time online refill, the process is documented step by step in this how to order prescriptions online guide — prescription first, licensed seller second, small first order third.
Before filling from any seller — online or local — verify them. A working VIPPS seal that resolves to a live NABP record, a real U.S. street address, and a prescription requirement that cannot be waived. A transparency page like this one about Metformin4You is a reasonable example of the standard to expect.
Most topicals and oral agents are available as low-cost generics, and the same tablet or cream can cost several times more at one licensed pharmacy than another. Biologics are usually covered fully through copay assistance programs. A two-minute comparison across licensed U.S. sellers is a useful habit to build. Begin with the current Metformin price comparison as a live demonstration of how wide the spread runs.
Open the price comparison